Acute Coronary Syndrome Market

DelveInsight’s Acute Coronary Syndrome market report provides a comprehensive understanding of the Acute Coronary Syndrome, historical and forecasted epidemiology, as well as Acute Coronary Syndrome market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan). 

Key Highlights from the Acute Coronary Syndrome Market Report

• According to the American Heart Association, an estimated 5–8 million patients visit the emergency department each year for chest pain, with 20–25 percent being diagnosed with Acute Coronary Syndrome.

• According to the findings of a study conducted by Ballerino et al. (2020), patients diagnosed with Acute Coronary Syndrome were statistically significantly older than those who did not have Acute Coronary Syndrome, with a higher prevalence of males.

• Key players, such as Regeneron, Sanofi, DalCor Pharmaceutical, CSL Behring, and others are actively working towards the development of novel therapies for Acute Coronary Syndrome treatment.  

• The emerging therapies in the Acute Coronary Syndrome market include Alirocumab, Dalcetrapib, CSL112, and several others.

• Dalcetrapib, the lead candidate of DalCor Pharmaceuticals, is a novel cholesterol ester transfer protein (CETP) inhibitor, a class of drugs that has been studied as a therapeutic to reduce the risk of cardiovascular events.

• Alirocumab, which is being developed by Regeneron and Sanofi, has shown promising results in an Acute Coronary Syndrome trial.

For a better understanding of the disease, request for sample @ Acute Coronary Syndrome Market Outlook

The Acute Coronary Syndrome market report also offers comprehensive coverage of the current treatment practices, emerging drugs, Acute Coronary Syndrome market share of the individual therapies, current and forecasted Acute Coronary Syndrome market Size from 2018 to 2030 segmented by seven major markets.

Acute Coronary Syndrome: Overview

Acute Coronary Syndrome (ACS) is an umbrella term that refers to a group of conditions that are associated with acute myocardial ischemia and/or infarction and are typically caused by a sudden decrease in coronary blood flow. Myocardial infarction with ST-segment elevation (STEMI), which generally represents an acute total coronary occlusion, myocardial infarction without ST-segment elevation (NSTEMI), and unstable angina (UA), with or without myocardial injury, are the traditional types of Acute Coronary Syndrome.

Acute Coronary Syndrome Epidemiology Segmentation

The Acute Coronary Syndrome report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Acute Coronary Syndrome Incident Cases

• Acute Coronary Syndrome Gender-Specific Incident Cases

• Acute Coronary Syndrome Type-Specific Incident Cases 

• Acute Coronary Syndrome Diagnosed and Treatable Cases

Acute Coronary Syndrome Treatment Landscape

The current Acute Coronary Syndrome treatment is mainly based on antiplatelet therapy. Aspirin, adenosine diphosphate P2Y12 receptor antagonists, and glycoprotein IIb/IIIa inhibitors are all well-established antiplatelet therapies used for Acute Coronary Syndrome treatment. Apart from this, some FDA-approved drugs such as Brilinta (AStraZeneca), Plavix (Sanofi-Aventis/Bristol-Myers Squibb), Ticagrelor (AstraZeneca), and Effient/Prasugrel (Eli Lilly and Company) are used to treat Acute Coronary Syndrome. 

Acute Coronary Syndrome Market

Key pharmaceutical companies such as Regeneron, Sanofi, DalCor Pharmaceutical, CSL Behring, and others are expected to launch new therapies in the Acute Coronary Syndrome market.

The introduction of Alirocumab, Dalcetrapib, CSL112, and others are expected to give the Acute Coronary Syndrome market a significant boost in the forecast period 2021-30 in the 7MM.

Get a detailed analysis of the market @ Acute Coronary Syndrome Market Research

Acute Coronary Syndrome Pipeline Therapies and Key Companies

• Alirocumab: Regeneron/ Sanofi

• Dalcetrapib: DalCor Pharmaceuticals

• CSL112: CSL Behring

Acute Coronary Syndrome Market Drivers

• Increased market opportunity

• Increasing Awareness

• Increase in the number of research initiatives

Acute Coronary Syndrome Market Barriers

• Diagnostic Delays

• Lack of approved therapies

• Chances of relapse

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2018-30

Acute Coronary Syndrome Key Companies: Regeneron, Sanofi, DalCor Pharmaceutical, CSL Behring, among others. 

Acute Coronary Syndrome Key Pipeline Therapies: Alirocumab, Dalcetrapib, CSL112, and others.

Acute Coronary Syndrome Segmentation: By Geography, By Acute Coronary Syndrome therapies

Analysis: Comparative and conjoint analysis of Acute Coronary Syndrome emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Acute Respiratory Distress Syndrome Market

Get a comprehensive analysis of Acute Respiratory Distress Syndrome pipeline therapies and key companies such as Faron Pharmaceuticals, PhaseBio Pharmaceuticals, Sage Therapeutics, Chimerix, Direct Biologics, Kiniksa Pharmaceuticals, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/